Navigation Links
Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Date:11/24/2008

PRINCETON, N.J., Nov. 24 /PRNewswire-FirstCall/ --Medarex, Inc. (Nasdaq: MEDX) today announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer. Studies suggest that the PD-1 signaling pathway may play an important role in tumor evasion and escape from host immune responses and may also promote the persistence of certain chronic viral infections.

The Phase 1b clinical trial is designed to primarily evaluate the safety and tolerability of repeated dosing of MDX-1106 in adult patients with solid tumors and will also provide a preliminary assessment of the anti-tumor activity of multiple doses of MDX-1106 (1, 3 or 10 mg/kg) in these patients. The tumors to be studied include malignant melanoma, renal cell cancer, castrate-resistant prostate cancer and non-small cell lung carcinoma. This open label study is expected to enroll up to 76 patients and will be conducted in multiple sites in the United States.

"We believe that anti-PD-1 antibodies could represent the next stage in immunotherapy with a promising mechanism of action and potential for marked synergy with anti-CTLA4 antibodies," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "Preliminary results from our single-dose Phase 1 study demonstrated an acceptable safety profile and initial evidence of anti-tumor activity in cancer. We look forward to the further development of this novel immunotherapy in cancer and, in a separate clinical trial, hepatitis C."

In May 2005, Ono entered into a collaboration agreement with Medarex to research and develop a fully human anti-PD-1 antibody for the treatment of cancer. The two companies plan to share the costs and responsibilities of researc
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Halifax Regional Medical Center Selects Micromedex Solutions from Thomson Reuters for Clinical Decision Support 59801 1Halifax Regional Medical Center Selects Micromedex Solutions from Thomson Reuters for Clinical Decision Support 59801 2Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 14542 1Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 14542 2Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 14542 3SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE 14539 1SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE 14539 2
Breaking Medicine News(10 mins):Health News:Educus.com Launches ICD-9 app for Apple iPhone and Android Devices 2Health News:Educus.com Launches ICD-9 app for Apple iPhone and Android Devices 3Health News:Fastrack Announces Enhancements to the Enterprise System for HME/Respiratory Providers 2Health News:Fastrack Announces Enhancements to the Enterprise System for HME/Respiratory Providers 3Health News:Fastrack Announces Enhancements to the Enterprise System for HME/Respiratory Providers 4Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 2Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 3Health News:Lung Cancer Alliance Praises Growing National Coalition 2Health News:Lung Cancer Alliance Praises Growing National Coalition 3Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 3